Loading…
← CockpitCompetitor Analysis › 137310.KS SD BiosensorOpen in the cockpit ↗

SD Biosensor137310.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Electronic Equipment/Instruments
Momentum leader 88
Mkt cap
$647M
US dollars, full cap
Free float
27%
of shares outstanding
$/day
$770,914
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-7.1 pp
WACC 5.5%
Hurdle
+19 pp
Req g minus delivered
Next earnings
134 days
1 Apr 2027
Close · KRW₩7,170
1D-2.5%
1W+0.6%
1M+5.4%
3M+9.5%
6M-14.8%
YTD-17.4%
1Y-25.4%
ATR %4.5%
52w lowhigh26.9% off high

What SD Biosensor does

Employees: 656

SD Biosensor at a glance

Size SD Biosensor (137310.KS) is a South Korea Health Care company (Electronic Equipment/Instruments) with a market value of $647M, the 306th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩7,170 on 18 Nov 2026.

Performance Over six months the shares fell 14.8%, against -27.0% for the median peer and -37.2% for the South Korea market (cap-weighted) — 7th highest of 21 in its peer set.

Growth Revenue grew 9.6% over the last twelve months (peer median +9.1%); the operating margin is -6.2% (peer median 6.6%).

Valuation It trades at 1.0× enterprise value to sales against a peer median of 1.3× (8th cheapest of 21).

Price implies For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is -16%, so the hurdle is +19 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 7.1 points below its cost of capital (5.5% WACC).

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026137310.KS 90Peer median 75
Six months, rebased to 100: SD Biosensor against the median of its 20 peers (local-currency closes).

SD Biosensor financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩763B₩711B₩695B₩656B₩2.93T
Revenue growth—+2%+6%-78%—
Gross profit₩275B₩224B₩241B₩29.2B₩1.38T
EBITDA₩71.1B₩51.4B₩87.2B-₩111B₩1.19T
Net income-₩831B-₩512B-₩98.4B-₩468B₩911B
Free cash flow₩31.2B₩300B₩77.7B-₩385B₩593B
Capital expenditure₩50.5B₩57.5B₩80.9B₩145B₩300B
Total debt₩97.9B₩669B₩607B₩604B₩24.8B

Quarterly statements and history in the cockpit →

SD Biosensor competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-60%-40%-20%0%-20%0%491000185750003850195940096530003090086450069620006120317450468530127120041960039200115180000640290650048410001060476830137310.KS6-month return →1-month return →
Up and to the right = strong over both horizons. SD Biosensor is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%+100%0×100×200×491000185750003850006120468530127120041960039200115180290650048410476830137310.KSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. SD Biosensor is the large dot.

Capital: growth delivered against growth the price implies

0%+20%0%20%185750003850195940096530039200000640290650001060137310.KSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. SD Biosensor is the large dot.

SD Biosensor competitors and peer comparison

How SD Biosensor compares with its peers

Peer set: Sector in the same market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

SD Biosensor against its 20 peers (data as of 18 Nov 2026)
Measure137310.KSPeer medianRank in peer set
1-month return+5.4%-8.3%2nd highest of 21
6-month return-14.8%-27.0%7th highest of 21
Distance from 52-week high-26.9%-49.0%4th highest of 21
Revenue growth (TTM)+9.6%+9.1%10th highest of 21
Operating margin-6.2%6.6%7th lowest of 21
EV / Sales1.0×1.3×8th cheapest of 21
Growth the price implies (Req g, 7 yrs)3.3%-6.6%2nd most demanding of 10
Growth delivered (Del g)-15.9%+12.2%lowest of 10
Hurdle (Req g minus delivered)+19.1 pp-15.7 ppmost demanding of 10
ROIC minus cost of capital-7.1 pp-0.4 pp6th lowest of 20
EV / EBITDA10.3×7.4×4th most expensive of 14
Net debt / EBITDA-1.9×1.2×4th least indebted of 15

Peer table

Peer set: Sector in the same market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
SD Biosensor 137310.KSSouth Korea$647M-15%+10%-6%1.0×3.3%-15.9%
Livsmed 491000.KSSouth Korea$687M-47%+89%-77%18.1×n/an/a
Chongkundang 185750.KSSouth Korea$609M-27%+6%4%0.5×-6.6%+5.4%
Boryung 003850.KSSouth Korea$554M-13%+6%6%0.9×-3.1%+12.6%
HK inno.N 195940.KSSouth Korea$783M-28%+7%12%1.3×-4.7%+12.2%
Seegene 096530.KSSouth Korea$808M-26%+13%13%1.2×-6.7%-15.9%
Daewoong 003090.KSSouth Korea$495M-28%+6%11%0.9×n/an/a
DongKook Pharmaceutical 086450.KSSouth Korea$855M+9%+13%10%1.2×-4.2%+10.6%
Daewoong Pharm 069620.KSSouth Korea$856M-33%+9%12%1.2×n/an/a
SK Discovery 006120.KSSouth Korea$866M+25%+24%3%0.8×n/an/a
Myung in Pharm 317450.KSSouth Korea$466M-20%+7%35%0.7×n/an/a
PROTEINA 468530.KSSouth Korea$460M+5%-59%-1,178%410.3×n/an/a
JS Link 127120.KSSouth Korea$458M-62%+39%-83%25.2×n/an/a
Komipharm International 041960.KSSouth Korea$454M-2%-6%-1%11.8×n/an/a
Oscotec 039200.KSSouth Korea$923M-32%+510%59%7.5×-10.2%+18.1%
Qurient 115180.KSSouth Korea$452M-56%-14%-512%84.4×n/an/a
Dong-A Socio 000640.KSSouth Korea$447M-8%+11%7%0.7×-6.6%+12.8%
L&C BIO 290650.KSSouth Korea$943M-37%+65%20%9.7×32.6%+21.0%
Hyundai Bioscience 048410.KSSouth Korea$424M-50%+78%-580%164.0×n/an/a
JW Pharmaceutical 001060.KSSouth Korea$423M-26%+9%13%0.7×-15.4%+7.2%
Rznomics 476830.KSSouth Korea$418M-76%-65%-1,112%215.1×n/an/a

Questions

Which companies are SD Biosensor's closest peers?
The cockpit's peer set: Livsmed (491000.KS), Chongkundang (185750.KS), Boryung (003850.KS), HK inno.N (195940.KS), Seegene (096530.KS), Daewoong (003090.KS), DongKook Pharmaceutical (086450.KS), Daewoong Pharm (069620.KS).
Is SD Biosensor expensive compared with its peers?
On ev / sales it trades at 1.0× against a peer median of 1.3×, 8th cheapest of 21 in its peer set. For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is -16%, so the hurdle is +19 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has SD Biosensor stock performed?
Over six months to 18 Nov 2026 the shares returned -14.8% against -27.0% for the median peer; over one year -25.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.